Syfovre and Izervay at a Glance: Do They Help Your Sight?
You want to know one thing: will these shots make your sight better? Here is the honest answer. Neither Syfovre nor Izervay has been shown to improve eyesight or restore lost vision1 What they do is slow the damage down. That is a real goal, but it is a different goal from getting sharper sight back, and knowing the difference helps you decide with clear eyes.
Both drugs treat an advanced stage of the dry form of macular degeneration. Syfovre and Izervay were approved in 2023 for geographic atrophy, a potentially debilitating type of dry age-related macular degeneration1 They are the first medicines the FDA has cleared for this condition, so they are new, and the long-term picture is still being learned.
These drugs ask for a real commitment, and they carry real risks alongside a modest benefit. Injections of Syfovre or Izervay can cause inflammation, bleeding beneath the clear lining of the eye, blurred vision, and a temporary increase in fluid pressure in the eye2 Most side effects are manageable, and we walk through the serious ones below so the decision is yours to make with your doctor, not a leap in the dark.
What Geographic Atrophy Is and Why These Drugs Exist
Geographic atrophy is a medical term for later-stage cases of dry age-related macular degeneration, where you get blind spots in your central view and your vision loses some sharpness, making reading, driving, and recognizing faces harder3 It affects the macula, the small central part of the retina you use for sharp, straight-ahead sight, which is why it hits the tasks that need fine detail.
Syfovre is also called pegcetacoplan, and Izervay is also called avacincaptad pegol. Both drugs target the immune system's complement pathway, a part of the body's defenses that research has tied to the retinal damage in dry AMD4 The idea is to quiet that overactive process so the patch of atrophy spreads more slowly across the retina.
This is not a pill or an eye drop you use at home. Syfovre and Izervay must be injected directly into the eye once per month, or every other month, on an ongoing basis1 That means repeated visits for as long as you and your doctor decide to continue, which is part of what makes the choice a real weighing of costs and benefits.
What the Trials Actually Found
The headline results are about the size of the damage, not about clearer sight. In the trials, Syfovre decreased the rate of lesion growth by 18% to 22% over two years, and Izervay decreased it by about 14% over one year4 In plain terms, the atrophy still grew and vision still declined; the treated patch simply spread somewhat more slowly than an untreated one.
Here is the part that surprises many patients. Two years of pegcetacoplan injections failed to postpone the loss of best-corrected visual acuity, reading ability, or patient-reported visual functioning5 The drugs changed the picture on a scan more than they changed what people could actually see day to day, and the same gap showed up for avacincaptad pegol.
The open question is whether slowing the damage now protects useful sight years down the road. Neither drug has demonstrated the ability to improve eyesight or restore lost vision1 Whether a benefit measured on a scan eventually becomes a benefit you can feel is exactly what longer studies will need to settle, so treatment today is a reasonable bet, not a sure thing.
How Strong Is the Evidence?
The approvals rest on large, carefully run studies, so the slowing effect itself is not in doubt. Both drugs slowed the development of geographic atrophy by about 14% to 20% compared with dummy (sham) injections1 That effect is genuine and repeatable across trials, but it is small, and small effects leave room for honest disagreement about whether they are worth it.
The main thing the trials measured was the area of atrophy on retinal scans, which is an anatomy measure rather than a vision measure. Slowing that anatomic growth did not translate into better visual acuity, reading ability, or visual functioning in the trials5 That gap between a better scan and better sight is the heart of the debate among retina doctors.
Doctors would be far more convinced by direct proof that patients see better or keep useful sight for longer. So far, neither drug has been shown to improve eyesight or restore lost vision1 Longer follow-up and results built around real-world vision, not just scan measurements, would strengthen the case a great deal.
Risks, Side Effects, and a Realistic Outlook
Most side effects come from the injection itself and tend to be short-lived. Injections of Syfovre or Izervay can cause inflammation, bleeding beneath the clear lining of the eye, blurred vision, and a temporary increase in fluid pressure in the eye2 Your care team checks for these at each visit, and most are treatable, so they are a reason for care and follow-up rather than for alarm.
A small number of serious problems are the real reason to think carefully. Some patients developed wet macular degeneration after taking the drugs, and there have been reports of retinal vasculitis, an inflammation that blocks blood flow to the retina and can lead to irreversible blindness2 These events are uncommon, but they are serious when they happen, which is why several retina specialists use these drugs cautiously and watch treated eyes closely.
It helps to hold realistic hopes rather than promises. Vision already lost to geographic atrophy is permanent3 These drugs are meant to slow further loss, not to bring back sight, so for most people the atrophy keeps growing, just more slowly, and success looks like a slower decline rather than a recovery.
When to Call Your Eye Doctor
After any eye injection, watch for new eye pain, increasing redness, a shower of new floaters, or a sudden drop in vision, and do not wait these out. Always see your provider if you experience sudden vision loss or eye pain3 These can be early signs of a serious reaction such as infection or inflammation, and getting checked the same day gives the best chance of protecting your eye.
Between any treatment visits, steady monitoring matters more than any single reading. Your eye care specialist will tell you how often you will need eye exams3 Ask your team what home checks make sense for you, and report any new distortion or blank spot in your central vision promptly rather than assuming it will pass.
Geographic atrophy and these injections are handled by an eye specialist, usually a retina specialist, not by a routine checkup alone. If you are considering Syfovre or Izervay, ask your eye doctor or optometrist for a referral to a retina specialist who can review your scans and talk through whether treatment fits your situation and your goals.
Common Questions About Syfovre and Izervay
The honest answer is no. Neither drug has been shown to improve eyesight or restore vision that is already lost1 Their aim is to slow how fast geographic atrophy grows, not to sharpen or recover sight. That is why the decision is really about slowing future loss, and why it helps to go in with clear expectations rather than hoping for a vision boost these drugs are not designed to give.
This is an ongoing treatment, not a one-time procedure. Syfovre and Izervay must be injected directly into the eye once per month, or every other month, on an ongoing basis1 That schedule continues for as long as you and your retina specialist decide to keep treating, so it is worth asking up front what the visit rhythm would look like for you and how you would fit it into daily life.
The effect is real but modest. In the trials, the drugs slowed the development of geographic atrophy by about 14% to 20%1 In everyday terms, the patch of damage still spread and vision still declined, just somewhat more slowly than it would without treatment. Whether that difference is worth the injections and risks is a personal call you make with your doctor.
No, and it helps to be clear about that from the start. Vision lost to geographic atrophy is permanent3 These medicines are designed to slow further damage rather than to undo it, so thinking of them as a way to buy time keeps expectations honest and makes it easier to judge whether the trade-off feels right for you.
More Questions Patients Ask
Two serious problems stand out among the rarer risks. Some patients developed wet AMD after treatment, and there have been reports of retinal vasculitis, a rare inflammation that blocks blood flow to the retina and can lead to irreversible blindness2 These are uncommon, and your doctor weighs them against the possible benefit before recommending treatment, but they are exactly why this is a decision to make carefully and to revisit if anything changes in the treated eye.
The hesitation comes down to the gap between the scan and real sight. Slowing the atrophy on a scan did not lead to better visual acuity, reading, or visual functioning in the trials5 Some specialists question whether a benefit you cannot yet see is worth the cost, the repeated injections, and the small risk of a serious reaction, especially for someone whose vision is stable for now.
These medicines are given by an eye specialist, usually a retina specialist, so start by asking your eye doctor or optometrist for a referral. A retina specialist can review your scans, explain what treatment would and would not do for your specific case, and help you decide. In the meantime, always see a provider promptly if you have sudden vision loss or eye pain3
- Given my current vision, what would treatment realistically change for me?
- How will we measure whether it is actually helping?
- What are the warning signs of a serious reaction after an injection?
- How often would I need injections, and for how long?
- What happens if I choose to monitor and wait instead of treating now?
- American Academy of Ophthalmology (EyeSmart) (2024). What to Know About Syfovre and Izervay for Geographic Atrophy.
- American Academy of Ophthalmology (EyeSmart) (2024). What to Know About Syfovre and Izervay for Geographic Atrophy.
- Cleveland Clinic (2024). Geographic Atrophy: Symptoms, Causes & Treatment.
- National Eye Institute (NEI) (2023). Story of discovery: NEI-funded research paves way for new dry AMD drugs.
- American Academy of Ophthalmology (EyeNet Magazine) (2024). New Geographic Atrophy Drugs: The Good, the Bad, and the Unknown.